Reducing prostate size with Leuprelin before radiotherapy
Prostatic Size Reduction Following the Administration of Leuprorelin Acetate in Localized Prostate Cancer Prior to Radiation Therapy. Pilot Study.
This study tests whether giving Leuprelin to men with prostate cancer before radiation therapy can shrink the prostate and reduce side effects from the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 95 Years |
| Sex | Male |
| Sponsor | Consorci Sanitari de Terrassa Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Terrassa, Barcelona) |
| Trial ID | NCT06184464 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the reduction in prostate size following the administration of Leuprelin acetate prior to radiotherapy in men diagnosed with prostate cancer. The study focuses on patients who require hormonal treatment before starting radiation therapy, as hormonal androgen blockade has been shown to improve oncological outcomes. By assessing the prostate size reduction, the study seeks to determine if this approach can minimize the volume of tissue exposed to radiation, thereby reducing toxicity to surrounding healthy organs. The evaluation will occur approximately two months after initiating treatment with Leuprelin.
Who should consider this trial
Good fit: Ideal candidates are men with a positive biopsy for prostate cancer who require hormonal treatment before radiotherapy.
Not a fit: Patients with prostate sizes less than 20 cc, positive lymph nodes, metastatic disease, or those who have previously undergone pelvic radiation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes and reduced side effects for patients undergoing radiotherapy for prostate cancer.
How similar studies have performed: While there is evidence supporting hormonal treatment's role in reducing prostate size before radiation, this specific approach has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Man with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy Exclusion Criteria: Patients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies. Patients with Previous pelvic radiation therapy.
Where this trial is running
Terrassa, Barcelona
- Hospital de Terrassa — Terrassa, Barcelona, Spain (Recruiting)
Study contacts
- Study coordinator: nicolas feltes
- Email: nicofeltes_81@hotmail.com
- Phone: 619-819-9500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.